Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy

Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study

The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.

Inclusion Criteria:

• Women and men who had a clinic and biopsy-proven idiopathic membranous nephropathy;
• 6.0g≥24 hour urinary protein≥1.0g;
• serum albumin concentration≥26g/L;
• Chronic Kidney Disease (CKD)≤3 stage (eGFR>30ml/min/1.73m2 MDRD);
• Willing to participate in the trial and signed an informed consent.

Exclusion Criteria:

• Secondary membranous nephropathy;
• Patients with one of the following circumstances- malignant tumors or malignancy, HIV infection, a history of mental illness, any serious systemic infection, serious gastrointestinal diseases, circulating hepatitis B surface antigens positive or persistent abnormal serum transaminase, abnormal glucose metabolism or diabetes mellitus;
• Pregnant and lactating women;
• Undergoing other clinical trials.